Placebo
Drug0 mcg/inhalation, 2 inhalations QID
NCT Number: NCT01476904
E004-C2 is a continuation of E004-C for safety evaluations with additional 3 months to be able to assess the 6-month safety profile for E004 (epinephrine inhalation) versus placebo in a double-blinded manner.
Looking for future studies?
Notify Me12 year–75 year
All sexes
Interventional
Phase 3
Amphastar Site 0006, Costa Mesa, California, United States
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
0 mcg/inhalation, 2 inhalations QID
220 mcg/inhalation, 2 inhalations QID
125 mcg/inhalation, 2 inhalations QID
Time frame: up to 12 weeks
Recording of all adverse events experienced during the course of the study
Time frame: Study visit 4, 8 and 12, greater than one hour after last dose
A 12-lead ECG (routine and QT/QTc) will be measured and recorded, provided that dosing of study drug has been performed greater than 1 hour prior to conducting the measurements.
Time frame: up to 12 weeks
Review use of resuce inhaler for treatment of asthma exacrbations occuring between doses of study medication.
Amphastar Pharmaceuticals, Inc.
Industry
A 3-month Safety Evaluation Extension to the 12-week E004-C Study in Asthma Patients (A Double Blinded, Placebo-controlled, Parallel, 3-month Safety Study in Adolescent and Adult Patients With Asthma)
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07612384
Asthma, Bronchial Diseases
Islamabad, Pakistan
View Trial DetailsNCT07440953
Asthma, Bronchial Diseases
Muzaffargarh, Punjab Province, Pakistan
View Trial DetailsNCT05137132
Airway Obstruction, Asthma
Ålesund, More and Romsdal, Norway
View Trial DetailsNCT06617143
Anxiety Disorders, Asthma
Ardahan, Turkey (Türkiye)
View Trial Details